Figure 5. Effect of rituximab on clonogenic MM progenitors in vitro.
MM colony formation following treatment of bone marrow mononuclear cells depleted of CD34+ and CD138+ cells with rituximab or 10% human serum (compl.). Results are presented as a percentage of the untreated control group. P < .01 for the rituximab and rituximab plus complement groups compared to the untreated (control) group by Student t test (n = 3).